Aarti Pharma Labs Quarterly Results for Trading Insights
In Mar 2026, Aarti Pharma Labs (AARTIPHARM) reported revenue ₹596 Cr and net profit ₹61 Cr — revenue +6.0% YoY. Browse AARTIPHARM income statement for revenue, profit, balance sheet and cash flow data.
AARTIPHARM Quarterly Results — Revenue, Profit & EPS Highlights
Aarti Pharma Labs latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Aarti Pharma Labs share price chart.
- Revenue of ₹596 Cr in Mar 2026 (+9.6% vs Jun 2026, +6.0% vs Mar 2025)
- Net Profit of ₹61 Cr in Mar 2026 (-19.7% vs Jun 2026, -30.7% vs Mar 2025)
- EBITDA of ₹127 Cr in Mar 2026 (-11.8% vs Jun 2026)
- Operating Margin of 19.0% in Mar 2026 (-6.0pp vs Jun 2026)
- Earnings Per Share of ₹6.74 in Mar 2026 (-19.8% vs Jun 2026)
Aarti Pharma Labs Quarterly Results — Revenue, EBITDA, Net Profit & EPS
AARTIPHARM quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 596 | 544 | 418 | 562 | 388 | 9.6% | 6.0% |
| Net Profit (₹ Cr) | 61 | 76 | 28 | 88 | 50 | - | - |
| EBITDA (₹ Cr) | 127 | 144 | 74 | 144 | 95 | - | - |
| EPS (₹) | 6.74 | 8.40 | 3.08 | 9.75 | 5.46 | - | - |
| Operating Margin (%) | 19.0% | 25.0% | 18.0% | 26.0% | 24.0% | - | - |
AARTIPHARM Share Price Trend — 1-Year Movement Across Quarterly Results
Aarti Pharma Labs 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore AARTIPHARM stock price history to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
AARTIPHARM vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Aarti Pharma Labs latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹463,071.60 Cr | 1875.1 | 15,018 | 2,710 | -5.6% | - | 18.0% | 165.9 |
|
Divis Laboratories
Mar 2026 |
₹225,157.18 Cr | 8588.0 | 2,986 | 751 | -5.0% | - | 25.2% | 303.4 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4971.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 431.9 |
|
Cipla
Mar 2026 |
₹117,137.57 Cr | 1431.1 | 6,612 | 543 | -9.3% | - | 8.2% | 208.3 |
|
Zydus Life Science
Mar 2026 |
₹113,855.38 Cr | 1115.6 | 7,569 | 1,341 | -4.3% | - | 17.7% | 88.2 |
All amounts in ₹ Crores